Utility of molecular tools for extended adjuvant endocrine therapy decisions in early breast cancer

Future Oncol. 2017 Dec;13(30):2733-2736. doi: 10.2217/fon-2017-0427. Epub 2017 Nov 23.

Authors

Domen Ribnikar¹, Philippe L Bedard¹

Affiliation

¹ Division of Medical Oncology & Hematology, Department of Medicine, University of Toronto & Princess Margaret Cancer Centre, Toronto, ON, M5G 1Z9, Canada.

PMID: 29168649
DOI: 10.2217/fon-2017-0427

No abstract available

Keywords: PAM-50; biomarker; early breast cancer; endocrine therapy; gene expression profiling; late relapse; oncotype DX; prediction.

Publication types

Editorial

MeSH terms

Antineoplastic Agents, Hormonal / administration & dosage
Antineoplastic Agents, Hormonal / adverse effects
Antineoplastic Agents, Hormonal / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Biomarkers, Tumor*
Breast Neoplasms / drug therapy*
Breast Neoplasms / genetics*
Breast Neoplasms / pathology
Clinical Decision-Making*
Female
Gene Expression Profiling
Humans
Neoplasm Staging
Prognosis
Recurrence
Treatment Outcome

Substances

Antineoplastic Agents, Hormonal
Biomarkers, Tumor